BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37175010)

  • 1. Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.
    Teuwen LA; Roets E; D'Hoore P; Pauwels P; Prenen H
    Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
    Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
    Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.
    Popa AM; Stejeroiu MA; Iaciu C; Olaru M; Orlov Slavu C; Parosanu A; Stanciu IM; Pirlog C; Pavel S; Nitipir C
    Cureus; 2023 Dec; 15(12):e50709. PubMed ID: 38111812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
    Caputo V; De Falco V; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Martini G; Corte CMD; Ciardiello D; Poliero L; De Vita F; Orditura M; Fasano M; Franco R; Caraglia M; Avitabile A; Scalamogna R; Marchi B; Ciardiello F; Troiani T; Napolitano S
    Ther Adv Med Oncol; 2022; 14():17588359221096878. PubMed ID: 35547096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
    Pinet S; Durand S; Perani A; Darnaud L; Amadjikpe F; Yon M; Darbas T; Vergnenegre A; Egenod T; Simonneau Y; Le Brun-Ly V; Pestre J; Venat L; Thuillier F; Chaunavel A; Duchesne M; Fermeaux V; Guyot A; Lacorre S; Bessette B; Lalloué F; Durand K; Deluche E
    Front Oncol; 2023; 13():1104659. PubMed ID: 36923436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
    Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
    Johnson DB; Dahlman KH; Knol J; Gilbert J; Puzanov I; Means-Powell J; Balko JM; Lovly CM; Murphy BA; Goff LW; Abramson VG; Crispens MA; Mayer IA; Berlin JD; Horn L; Keedy VL; Reddy NM; Arteaga CL; Sosman JA; Pao W
    Oncologist; 2014 Jun; 19(6):616-22. PubMed ID: 24797823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
    Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
    Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
    Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
    ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
    Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
    [No Abstract]   [Full Text] [Related]  

  • 16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
    Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
    J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
    Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
    Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.